Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 6/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.55 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.55 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.51 |
| ▸ | FEN1 | P39748 | 2/20 | 0.51 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4236352 | 0.86 | ALDH1A1 (0.58) | POLBL3MBTL1ALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL4235827 | 0.85 | ALDH1A1 (0.61) | POLBL3MBTL1ALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL25026436 | 0.82 | ALOX5AP (0.57) | CYP2A13POLBL3MBTL1HIF1AEPAS1 | |
| SCHEMBL15915825 | 0.82 | CYP2A13 (0.56) | CYP2A13POLBL3MBTL1HIF1AEPAS1 | |
| SCHEMBL17428664 | 0.80 | DCUN1D1 (0.46) | ALDH1A1LMNAKDM4ESCN9A | |
| SCHEMBL19083727 | 0.79 | OPRL1 (0.46) | ALDH1A1KDM4ESCN9AMAOA | |
| SCHEMBL20697775 | 0.78 | OPRL1 (0.46) | POLBALDH1A1KDM4ESCN9AMAOA | |
| SCHEMBL16704827 | 0.78 | HIF1A (0.82) | L3MBTL1HIF1AEPAS1ALDH1A1LMNA | |
| SCHEMBL1438683 | 0.77 | CYP2A13 (0.66) | CYP2A13L3MBTL1HIF1AEPAS1CYP2C9 | |
| SCHEMBL12569577 | 0.77 | CYP2A13 (0.61) | CYP2A13POLBL3MBTL1HIF1ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137653-A1 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | INFLAYZME PHARMACEUTICALS LTD. (CA) | 2009-05-28 | — | — | US | disclosed |
| EP-1871357-A2 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | Inflazyme Pharmaceuticals, Ltd. (CA) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006108149-A2 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137653-A1 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | CYP2A6, CYP2B6, CYP2D6 | CYP2A13 19/4885POLB 1591/4885L3MBTL1 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.